The T1799A point mutation is present in posterior uveal melanoma by Janssen, C S et al.







5 and F Roberts*,2
1Division of Infection & Immunity, FBLS, University of Glasgow, Glasgow, UK;
2Department of Pathology, Western Infirmary, Glasgow, UK;
3School of
Engineering and Science, University of the West of Scotland, Paisley, UK;
4Sherbrooke Consultants, 22 Sherbrooke Drive, Glasgow, UK;
5Tennent Institute
of Ophthalmology, Gartnavel General Hospital, Glasgow, UK
An activating mutation in exon 15 of the BRAF gene is present in a high proportion of cutaneous pigmented lesions. Until recently this
mutation had however only been identified in one case of posterior uveal melanoma. Despite this apparent lack of the BRAF
mutation, inappropriate downstream activation of the Ras/Raf/MAPK pathway has been described in posterior uveal melanoma.
Based on the already recognised morphological and cytogenetic heterogeneity in uveal melanoma, we hypothesised that the BRAF
mutation may be present in uveal melanoma but only in some of the tumour cells. In this study, we analysed 20 ciliary body and 30
choroidal melanomas using a nested PCR-based technique resulting in the amplification of a nested product only if the mutation was
present. This sensitive technique can identify mutated DNA in the presence of wild-type DNA. The mutation was identified in 4 of 20
(20%) ciliary body and 11 of 30 (40%) choroidal melanomas. Further analysis of separate areas within the same choroidal melanoma
demonstrated that the mutation was not present in the entire tumour. In conclusion, the T1799A BRAF mutation is present in a
proportion of posterior uveal melanomas but within these tumours the distribution of the mutation is heterogeneous.
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Mutations in the BRAF gene (a member of the Raf family that
encodes a serine/threonine protein kinase) have been shown to
occur in the majority of cutaneous melanomas (Brose et al, 2002;
Davies et al, 2002). In particular a single point mutation in exon 15
(T1799A), which results in constitutive kinase activity and
unregulated signal transduction, is involved in up to 80% of cases
(Brose et al, 2002; Davies et al, 2002). Despite the high incidence of
this mutation in cutaneous melanoma, several studies have shown
that it is not present in posterior uveal melanoma (Cohen et al,
2003; Weber et al, 2003). The BRAF mutation has however been
identified in several primary uveal melanoma cell lines and
recently Malaponte et al (2006) identified the mutation in one
primary uveal melanoma. Recently, we have identified that the
mutation also occurs in iris melanoma (Henriquez et al, 2007). The
reason for this discrepancy in reporting of the BRAF mutation is
not clear. Cutaneous and uveal melanoma share a common
embryological origin from cells of the neural crest and often
exhibit similar histological characteristics (Hogan et al, 1971).
However, it is well-recognised that individual uveal melanomas
display considerable morphological and cytogenetic heterogeneity
(COMS, 1998; Sandinha et al, 2006; Maat et al, 2007). To date the
methods used to identify the BRAF mutation have not taken this
potential genetic heterogeneity into account. The negative results
from previous studies may reflect the inability of the technique
used to identify the mutation in a minority of cells in a background
of cells containing the wild-type BRAF gene.
To address this problem we used a nested PCR-based technique,
which would result in the amplification of a nested product only if
the mutation was present. This technique was used to screen
posterior uveal melanoma samples for the presence of the BRAF
mutation and secondly to examine separate areas within individual
tumours to confirm genetic heterogeneity.
MATERIALS AND METHODS
Case selection
Archival formalin- or gluteraldehyde-fixed, paraffin-embedded tissue
sections from choroidal and ciliary body melanomas were retrieved
from the Eye Pathology Files, Western Infirmary Glasgow. Clinical
and histological details (such as age, sex, metastasis, largest basal
dimension of tumour, cell types, presence of closed vascular loops)
were obtained from the pathology report. A total of 30 choroidal
melanomas and 20 ciliary body melanomas were selected for this
study. This project received the full approval of the West Ethics
Committee, North Glasgow Hospitals, and adhered to the tenets of
The Declaration of Helsinki. Normal tissue adjacent to the tumour
was used as a negative control. The SKmel-28 cell line was used as a
positive control. Human foreskin fibroblasts (HFF) were used as a
negative control for developing the technique.
Genomic DNA isolation
One unmounted haematoxylin and eosin- (H&E) stained 4mm
section was examined from each case and appropriate areas of
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stumour and normal tissue identified. A 15ml droplet of proteinase K
(1% solution in 10mM Tris (pH 8.5) and 1mM EDTA) was added to
the relevant areas on the section and the cells scraped with a fresh
scalpel blade until suspended in the droplet. The solution was then
pipetted into a 0.2ml PCR tube. The samples were incubated at 551C
f o r2 0h .F o l l o w i n gt h ea d d i t i o no f1 5m lo fw a t e r ,p r o t e i n a s eKw a s
inactivated by incubation at 951C for 8min. The isolated DNA was
stored at 41C until further use in PCR. For all choroidal and ciliary
body melanomas one area of tumour was sampled for investigation.
To investigate heterogeneity within the tumour additional areas of
tumour were sampled from 12 of the choroidal melanoma cases.
For control DNA SKmel-28 and HFF cells were harvested and
pelleted by centrifugation at 1500g,4 1C, for 10min, and washed
with PBS. The cells were incubated for 3h at 501C in 1 volume lysis
solution, (100mM Tris pH 7.4, 100mM EDTA pH 8.0, 1% SDS,
1mgml
 1 proteinase K). The lysate was treated by phenol and
chloroform extraction, and the aqueous layer centrifuged at
12000g for 15min at 41C. After isopropanol/0.2 M NaCl precipita-
tion at room temperature for 10min, the sample was centrifuged at
12000g for 10min at 41C. Pellets were washed three times with
75% ethanol, air dried, and dissolved in H2O.
Polymerase chain reaction
Primary PCR Primary PCR amplification reactions were per-
formed in a 25ml reaction using ReddyMix (ABgene, Epson, UK)
containing 5pmol of forward (50-TCATAATGCTTGCTCTGATA
GGA-30) and reverse (50-GGCCAAAAATTTAATCAGTGGA-30)
primer and 5ml of gDNA template isolated from tumour cells.
Reactions consisted of an initial denaturation at 951C for 3min
followed by 28 cycles of denaturation at 951C for 20s, annealing for
30s at 551C and extension at 721C for 45s. A final extension was
carried out at 721C for 10min. Three reactions were carried out per
DNA extraction.
Secondary PCR Secondary PCRs were performed in a 20ml reaction
using ReddyMix (ABgene) containing 5pmol of mutation-specific
forward (50-GATTTTGGTCTAGCTACACA-30) primer, which was
optimised to anneal only at the mutation site, if present. Also included
were 5pmol of wild-type forward primer (50-GCTCTGATAGGAAAA
TGAGATC-30) and reverse primer (50-GTGGAAAAATAGCCTCAA
TTC-30), with 2ml of template from the primary PCR. Reactions
consisted of an initial denaturation at 951C for 3min followed by 35
cycles of denaturation at 951C for 20s, annealing for 30s at 501Ca n d
extension at 721C for 45s. A final extension was carried out at 721Cf o r
10min. All reactions were carried out in triplicate.
Polyacrylamide Gel Electrophoresis
Precast polyacrylamide gels (6%) (Invitrogen, Paisley, UK) were
immersed in TBE buffer. Samples were loaded on to the gel and
electrophoresed for 1h at 100V.
Silver staining
Following electrophoresis the gels were immersed in fixing
solution (10% ethanol, 0.007% acetic acid) for 5min. A further
50ml of fixing solution containing 0.2g silver nitrate was added,
and gels stained for 10min. Gels were washed two times in
de-ionised water for 20s and 1min, respectively. The gel was
developed by immersing it immediately in 150ml of 0.75 M NaOH
containing 0.007% formaldehyde until bands appeared. Finally, the
gel was rinsed in de-ionised water and washed two times in fixing
solution. A band of 200 nucleotides (nt) was obtained in each
sample representing the wild-type gene. A further band at 100nt
was present in cases that contained the T1799A mutation. When
the wild-type reverse primer was used the second band was
approximately 140nt. In addition, in reactions from DNA
extracted from archival paraffin-embedded sections, occasional
additional bands were present. This artefact was considered
unavoidable as DNA extracted from the paraffin tissue is highly
fragmented, and some of the small fragments can lead to self-
priming within the reaction.
Statistical analysis
For choroidal melanoma the relationship of known survival time
with BRAF mutation, sex, cell type and vascular loops was tested
one at a time by a Kaplan–Meier analysis and the relationship of
survival time with age and tumour diameter were tested using the
‘Regression with Life Data’ function of Minitab 13.1 (Minitab Inc.,
State College, PA, USA). The relationship between known survival
time and the other variables was also considered in a single
multivariate survival analysis. When several tumour areas were
sampled from a single tumour association with cell type were
assessed by Fisher’s exact test.
It was not possible to do this analysis for ciliary body melanoma
due to the smaller number of cases and absence of survival data.
The relationship between age and the presence of the BRAF
mutation was assessed by a two-tailed 2-sample t-test.
RESULTS
SKmel-28 and HFF
Positive and negative BRAF mutation controls were used to ensure
the optimisation of the method. Two products of 200 and 100 base
pairs (bp) were obtained for SK-mel28, which contains the T1799A
BRAF mutation and one product of 100bp for HFF negative
control (Figure 1). Identical results were obtained in replicate
experiments including titration and kinetic analysis, covering 36
replicates (see Figure 1) Mixing DNA from SKmel-28 and HFF
showed that the second (100bp) band, indicating the presence of










Figure 1 Silver-stained polyacrylamide gel showing a single band at 200nt for human foreskin fibroblast (HFF) DNA (A) and an additional band at 100nt
for SKmel-28 cell DNA (A). Mixed DNA from HFF and SKmel-28 (B) also shows molecular markers at 200 and 100bp respectively.
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sproduct of 200bp (Figure 1), when sampling a mixture of one
SKmel-28 cell in 100HFF cells.
Choroidal and ciliary body melanomas
The T1799A mutation was identified in 4 of the 20 ciliary body
melanomas studied and in 11 of the 30 choroidal melanomas
examined.
In addition, sampling of several different areas was undertaken
in the 11 positive cases of the choroidal melanoma cases to
investigate potential heterogeneity of the T1799A mutation within
the tumour sample. Between three and six areas were sampled
depending on tumour size (Figure 2; Table 1). Five of the 11 cases
contained the BRAF mutation in all areas sampled. In four out of
the 11 cases the mutation was present in one sampled area only. In
two cases the mutation was present in two sampled areas.
Clinical and pathological details
Ciliary body
BRAF-positive cases: Of the four positive cases out of 20 there
were three enucleation specimens and one local resection speci-
men from two men and two women with an average age of 33.5
years (range, 16 to 48 years). Two of the four patients were alive
and well, one had died from an unrelated cause. We were unable to
obtain clinical follow up information on the fourth patient. The
pathology report and original sections were available for review in
all cases. The average largest dimension of the tumour was
15.5mm (range, 10–20mm). Three tumours were composed of
spindle cells and one was of mixed spindle and epithelioid cells.
Three of the tumours contained closed vascular loops.
BRAF negative cases: Of the 16 cases out of 20 negative cases
there were eight enucleations and eight local resection specimens
from seven men and nine women with an average age of 59.6 years
(range, 30–80 years). One patient had died of metastatic disease
and six patients were alive and well at last follow up. We were
unable to obtain clinical follow up information on the remaining
nine patients. The pathology report and original sections were
available for review in all cases. The average largest dimension of
the tumour was 12.7mm (range, 5–22mm). Seven tumours were
composed of spindle cells and nine were mixed spindle and
epithelioid cells. Seven tumours contained closed vascular loops.
The clinical and pathological details are summarised in Table 2.
There were no convincingly statistically significant associations
between the presence of the BRAF mutation and clinical and
pathological features.
Choroid
BRAF-positive cases: Of the 11 positive cases out of 30 there were
six enucleations and five local resection specimens from six
women and five men with an average age of 51 years (range, 42–69
years). Clinical follow up was available in all cases. Eight of the
patients had died from metastatic tumour and three were alive and
tumour free at last follow up. The pathology report and original
sections were available for review in all cases. The average largest
dimension of the tumour was 14.5mm (range 10–18mm). Five
tumours were composed of spindle cells, one of epithelioid cells
and five were mixed spindle and epithelioid cells. Nine tumours
contained closed vascular loops.
BRAF-negative cases: Of the 19 positive cases out of the 30
negative cases there were 12 enucleations and seven local resection
specimens from 11 women and eight men with an average age of
57.4 years (range, 19–75 years). Clinical follow up was available in
all cases. Eight of the patients had died from metastatic tumour
and 11 were alive or had died from other causes. The pathology
report and original sections were available for review in all cases.
The average largest dimension of the tumour was 14.7mm (range,
8–23mm). Eleven of the tumours were composed of spindle cells
and eight were of mixed spindle and epithelioid cells. Twelve
tumours contained closed vascular loops.
The clinical and pathological details are summarised in Table 2.
The Kaplan–Meier survival curve for patients with tumours with
and without the BRAF mutation is shown in Figure 3. There was a
trend for BRAF-positive tumours to show a shorter survival but
this was not statistically significant. There were no statistically
significant associations between any other clinical or pathological
characteristics and the presence of the BRAF mutation. Further-
more, in tumours where several areas of the tumour were dissected
there was no association between cell type in the individual areas
and presence of the mutation.
100 nt
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Figure 2 (A) Tissue section of enucleation specimen after dissection of four tumour areas (1–4) and one normal tissue area (N). (H&E, magnification
 1.25). (B) Silver-stained polyacrylamide gel showing a single band at 200bp in the four corresponding tumour samples and in the normal tissue sample
indicating lack of the T1799A point mutation in this case. (C) Tissue section of local resection specimen after dissection of four tumour areas (1–4). (H&E,
magnification  2). (D) Silver-stained polyacrylamide gel showing an additional band at 100nt in samples 2 and 4 indicating the presence of the mutation in
these samples. There is an additional band between 200 and 100nt representing a PCR artefact. Samples 1 and 3 show only one band at 200nt indicating
lack of the mutation.
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Activating mutations in the BRAF gene have been identified in many
human cancers, with the highest frequency of mutations found in
cutaneous melanomas (Brose et al, 2002; Davies et al, 2002; Goydos
et al, 2005). In melanoma, these BRAF mutations are found in two
small regions of the kinase domain of the BRAF molecule. The
p r e d o m i n a n tm u t a t i o no c c u r si ne x o n1 5o ft h eBRAF gene with a
single T-to-A substitution at nucleotide 1799, although a smaller
number of mutations have also been found in a region of exon
11(Brose et al, 2002; Davies et al, 2002; Goydos et al, 2005). These
mutations have been shown to be present in 66 to 80% of cutaneous
melanomas and have also been detected in up to 82% of melanocytic
nevi(Pollock et al, 2003). The mutation has also been reported in 22–
40% of conjunctival melanomas and recently our group has identified
this mutation in 48% of 19 iris melanomas (Gear et al, 2004; Spendlove
et al, 2004; Henriquez et al, 2007). However, there have been several
studies, in uveal melanoma including primary and metastatic choroidal
and ciliary body melanomas and the BRAF mutation has only been
identified in one case (Malaponte et al, 2006). Despite this apparent
lack of the characteristic BRAF mutation, inappropriate downstream
MAPK component activation has been reported by Weber et al (2003)
w h of a i l e dt oi d e n t i f yt h eBRAF mutation in 42 primary uveal
melanoma but showed immunohistochemical staining for ERK in 86%
of these cases. Similarly, Zuidervaart et al (2005) found constitutive
activation of the MAPK pathway in 11 uveal melanoma cell lines and
19 primary tumours by performing western blot or immunohisto-
chemistry for the various pathway components. However, an activating
BRAF mutation was found in only one cell line. Using the more
sensitive nested PCR approach we have identified the T1799A BRAF
mutation in 4 of 20 (20%) ciliary body melanomas and 11 of 30 (40%)
choroidal melanomas.
The majority of other studies have used some form of direct
sequencing to identify this mutation (Cruz et al, 2003; Edmunds
et al, 2003; Weber et al, 2003). Sequencing would not be able to
detect mutant alleles present at low frequency because of somatic
mosaicism. Although more sensitive techniques including the
ligase detection assay and high amplicon melting PCR have been
used to identify the BRAF mutation in other tissues including
cutaneous melanoma they have not been applied to uveal
melanoma (Turner et al, 2005; Willmore-Payne et al, 2005).
Recently, Maat et al (2008) detected the BRAF mutation in 6 of 45
uveal melanomas using the more sensitive technique of pyropho-
sphorolysis-activated polymerisation. In this technique a product
is amplified only when the mutation is present even in the
presence of tens of thousands of wild-type templates. The nested
PCR approach described herein was developed using the SKmel-28
cell line, which is known to harbour the T1799A mutation.
Consistent results were obtained using this technique and the
mutation could also be detected at low frequency when DNA from
SKmel-28 was mixed with wild-type DNA extracted from HFF. The
robustness of the primers was established by thoroughly testing
the annealing specificity of both wild type-specific and mutation-
specific primers designed to anneal to the same site. By dilution of
the mutated DNA it was estimated that this technique could detect
at least one copy number of the mutation in 100 wild-type genes,
and is therefore significantly more sensitive than techniques
requiring direct sequencing.
The sensitivity of the PCR technique utilised would make it
possible to identify mutant DNA in the presence of wild-type DNA.
As separate samples from the same tumour did not always reveal the
Table 1 The number of mutated and non-mutated tumour areas in
cases with the T1796A BRAF mutation













A 1 5 16.67
B 1 4 20.0
C 2 4 33.33
D 1 4 20.0
E 1 2 33.3
F 2 2 50.0
Total 8 21 38.10















BRAF mutation 33 (16–48) 9F:7M 15.5 (10–20) 3:0:1 3:1 0:3:1 N/A
BRAF wild type 59 (30–80) 2F:2M 12.7 (5–22) 7:0:9 7:9 1:6:9 N/A
Choroid
BRAF mutation 51 (42–69) 6F:5M 14.5 (10–18) 5:1:5 9:2 8:3:0 4–337







































Figure 3 Kaplan–Meier survival curve showing the relationship between
time as surgery and survival rate for patients with tumours with and without
the BRAF mutation.
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smutant band, this supports the theory that this mutation is only
present in some of the tumour cells. Clonal heterogeneity,
particularly morphological heterogeneity is well recognised in uveal
melanoma (COMS, 1998) and the majority of tumours are
composed of variable proportions of epithelioid and spindle-shaped
cells. There have been few studies of cytogenetic heterogeneity in
uveal melanoma. Sandinha et al (2006) described a heterogenous
distribution of cells displaying monosomy three in uveal melanoma
and Maat et al (2007) described areas of unmethylated and
methylated RASSF1a within individual uveal melanomas. It is
therefore plausible that the BRAF mutation could also be distributed
heterogeneously. To address this problem we studied several
separate tumour areas in 11 choroidal melanomas positive for the
T1799A mutation. In six of the tumours positive for the BRAF
mutation it was observed that the mutation was present in some
areas of the tumour but not in others. However, it did not show any
association with the cell types in the different areas.
Although the results of this study confirm that the BRAF
mutation is heterogeneously distributed in uveal melanoma the
frequency of this mutation still appears considerably lower than in
cutaneous melanoma. This may be due to insufficient tumour
sampling. Both cutaneous and uveal tumours share a common
embryological origin from the neural crest but there are
considerable differences between the cutaneous and uveal
environment. For example, ultraviolet light is considered to be
an important risk factor in cutaneous melanoma. It has also been
suggested that exposure to ultraviolet light may be a key factor in
melanomas with the T1799A point mutation(Thomas et al, 2006).
Previous research has also shown that the BRAF mutation
frequency is lower in melanoma arising in sites protected from
sun exposure compared with those from sun-exposed sites(Cohen
et al, 2004). Although it is recognised that the BRAF mutation is
not a UV-signature mutation, it has been suggested that it could
still arise due to error-prone reduplication of UV-damaged DNA
(Thomas et al, 2006). UV exposure is not considered a major factor
in choroidal melanoma and this may in part explain the lower
frequency of the mutation in the cases studied. An alternative
explanation is that this BRAF mutation is an infrequent event in
uveal melanoma and the observed, inappropriate downstream
activation of the MAPK component is due to genetic alterations in
other components of this pathway.
In conclusion, we have shown that the BRAF mutation is present
in a proportion of posterior uveal melanomas and that within these
tumours the distribution of this mutation is heterogeneous. This
does not appear to carry any prognostic significance but may
provide an explanation for the observed upregulation of the MAPK
pathway in uveal melanoma.
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